CY1108990T1 - Φαρμακευτικος συνδυασμος αιθινυλεστραδιολης και δροπιρενονης για χρηση ως αντισυλληπτικο - Google Patents
Φαρμακευτικος συνδυασμος αιθινυλεστραδιολης και δροπιρενονης για χρηση ως αντισυλληπτικοInfo
- Publication number
- CY1108990T1 CY1108990T1 CY20091100446T CY091100446T CY1108990T1 CY 1108990 T1 CY1108990 T1 CY 1108990T1 CY 20091100446 T CY20091100446 T CY 20091100446T CY 091100446 T CY091100446 T CY 091100446T CY 1108990 T1 CY1108990 T1 CY 1108990T1
- Authority
- CY
- Cyprus
- Prior art keywords
- daily dosage
- ethinylestradiol
- active agent
- dosage units
- ethinylstradiol
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 2
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 2
- 229960002568 ethinylestradiol Drugs 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 238000012856 packing Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Μία φαρμακευτική σύνθεση περιλαμβάνει, ως ένα πρώτο ενεργό παράγοντα 6β, 7β, 15β, 16β-διμεθυλενο-3-οξο-17α-πρεγν-4-ένο-21, 17-καρβολακτόνη (δροσπιρενόνη) σε ποσότητα που αντιστοιχεί σε μία ημερήσια δοσολογία, κατά τη χορήγηση της σύνθεσης, από περίπου 2 mg ως 4 mg, και, ως ένα δεύτερο ενεργό παράγοντα, 17α-αιθινυλεστραδιόλη (αιθινυλεστραδιόλη) σε ποσότητα που αντιστοιχεί σε μία ημερήσια δοσολογία από περίπου 0.01 mg ως περίπου 0.05 mg, μαζί με έναν ή περισσότερους φαρμακευτικά αποδεκτούς φορείς ή έκδοχα. Σε μία συγκεκριμένη εφαρμογή, η σύνθεση αποτελείται από έναν αριθμό ξεχωριστά συσκευασμένων και μεμονωμένα αφαιρέσιμων μονάδων ημερήσιας δοσολογίας τοποθετημένων σε μία μονάδα συσκευασίας και προορισμένων για στοματική χορήγηση για μία περίοδο τουλάχιστον 21 συνεχόμενων ημερών, όπου οι εν λόγω μονάδες ημερήσιας δοσολογίας περιλαμβάνουν το συνδυασμό δροσπιρενόνης και αιθινυλεστραδιόλης. Η σύνθεση μπορεί να περιλαμβάνει περαιτέρω 7 ή λιγότερες μονάδες ημερήσιας δοσολογίας που δεν περιέχουν ενεργό παράγοντα ή που περιέχουν μόνο αιθινυλεστραδιόλη.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38627499A | 1999-08-31 | 1999-08-31 | |
EP99202826 | 1999-08-31 | ||
EP03017743A EP1380301B1 (en) | 1999-08-31 | 2000-08-31 | Pharmaceutical combination of ethinylestradiol and dropirenone for use as a contraceptive |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108990T1 true CY1108990T1 (el) | 2014-02-12 |
Family
ID=26153359
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100446T CY1108990T1 (el) | 1999-08-31 | 2009-04-14 | Φαρμακευτικος συνδυασμος αιθινυλεστραδιολης και δροπιρενονης για χρηση ως αντισυλληπτικο |
CY20091100784T CY1109252T1 (el) | 1999-08-31 | 2009-07-22 | Φαρμακευτικος συνδυασμος αιθινυλοιστραδιολης και δροσπιρενονης για χρηση ως αντισυλληπτικο |
CY2009015C CY2009015I2 (el) | 1999-08-31 | 2009-09-25 | Φαρμακευτικος συνδυασμος αιθινυλεστραδιολης και δροπιρενονης για χρηση ως αντισυλληπτικο |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100784T CY1109252T1 (el) | 1999-08-31 | 2009-07-22 | Φαρμακευτικος συνδυασμος αιθινυλοιστραδιολης και δροσπιρενονης για χρηση ως αντισυλληπτικο |
CY2009015C CY2009015I2 (el) | 1999-08-31 | 2009-09-25 | Φαρμακευτικος συνδυασμος αιθινυλεστραδιολης και δροπιρενονης για χρηση ως αντισυλληπτικο |
Country Status (26)
Country | Link |
---|---|
EP (4) | EP1380301B1 (el) |
JP (2) | JP4354667B2 (el) |
KR (2) | KR100857344B1 (el) |
AT (3) | ATE429231T1 (el) |
AU (4) | AU780330B2 (el) |
BG (1) | BG66114B1 (el) |
BR (1) | BR0014159A (el) |
CY (3) | CY1108990T1 (el) |
CZ (1) | CZ300514B6 (el) |
DE (5) | DE122009000007I2 (el) |
DK (3) | DK1380301T3 (el) |
EE (1) | EE05128B1 (el) |
ES (3) | ES2211580T3 (el) |
HK (3) | HK1047247B (el) |
HR (1) | HRP20070188B1 (el) |
HU (1) | HU227207B1 (el) |
IL (1) | IL148339A0 (el) |
ME (2) | MEP36008A (el) |
NO (1) | NO326860B1 (el) |
NZ (1) | NZ517845A (el) |
PL (1) | PL199028B1 (el) |
PT (3) | PT1380301E (el) |
RS (3) | RS20090134A (el) |
SI (3) | SI1598069T1 (el) |
TW (1) | TWI276436B (el) |
WO (1) | WO2001015701A1 (el) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4354667B2 (ja) * | 1999-08-31 | 2009-10-28 | バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト | 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ |
MXPA02006613A (es) * | 2000-01-18 | 2003-10-15 | Schering Ag | Drospirenona para terapia de reemplazo de hormonas. |
JO2334B1 (en) * | 2000-01-18 | 2006-06-28 | باير شيرنغ فارما اكتنجيسيلشافت | Drospirenone for hormone replacement therapy |
EP1216713A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
WO2002049674A1 (en) * | 2000-12-20 | 2002-06-27 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
CA2483554A1 (en) * | 2002-04-26 | 2003-11-06 | Schering Aktiengesellschaft | Treatment of hypertension in women receiving hormone replacement therapy |
US7786101B2 (en) | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
MY142989A (en) * | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
WO2005087194A1 (en) * | 2004-03-10 | 2005-09-22 | Schering Aktiengesellschaft | Compositions comprising drospirenone molecularly dispersed |
MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
EP1625849A1 (en) * | 2004-08-09 | 2006-02-15 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | Pharmaceutical composition comprising drospirenone and ethynylestradiol |
US8216611B2 (en) * | 2005-03-30 | 2012-07-10 | Mylan Pharmaceuticals Ulc | Combined-step process for pharmaceutical compositions |
UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
EP1767194A1 (de) * | 2005-06-09 | 2007-03-28 | Helm AG | Verfahren zur Herstellung von Adsorbaten des Drospirenons |
CN101489563A (zh) * | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
EP2063870A2 (en) * | 2006-09-16 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Oral modified release formulations |
EP1900359A1 (en) * | 2006-09-16 | 2008-03-19 | KAIROSmed GmbH | Oral modified release formulations containing drospirenon and 8-prenylnaringenin for use in female contraception |
MX2009010763A (es) * | 2007-04-05 | 2009-10-28 | Bayer Schering Pharma Ag | NUEVO REGIMEN DE DROSPIRENONA/17ß-ESTRADIOL, PRODUCTO FARMACEUTICO COMBINADO Y CONJUNTO DE ELEMENTOS (KIT) PARA SU APLICACION. |
HUP0700826A3 (en) * | 2007-12-20 | 2010-03-29 | Richter Gedeon Nyrt | Coated tablet containing drospirenone and process for producing the same |
WO2009112231A2 (en) * | 2008-03-10 | 2009-09-17 | Schuermann Rolf | New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen |
TW200946542A (en) * | 2008-03-10 | 2009-11-16 | Vladimir Hanes | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
WO2009138224A1 (en) * | 2008-05-14 | 2009-11-19 | Helm Ag | Pharmaceutical composition comprising drospirenone |
DE102008037025C5 (de) | 2008-08-08 | 2016-07-07 | Jesalis Pharma Gmbh | Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform |
EP2398461A1 (en) | 2009-02-18 | 2011-12-28 | Bayer Pharma Aktiengesellschaft | Formulation comprising drospirenone for subcutaneous or intramuscular administration |
UY32836A (es) | 2009-08-12 | 2011-03-31 | Bayer Schering Pharma Ag | Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato |
BR112012026115B1 (pt) * | 2010-04-15 | 2019-12-24 | Bayer Ip Gmbh | forma de dosagem oral sólida, seu uso, e unidade de acondicionamento |
US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
IT202100008834A1 (it) | 2021-04-08 | 2022-10-08 | Ind Chimica Srl | Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina |
WO2023152658A1 (en) | 2022-02-10 | 2023-08-17 | Lupin Limited | Slow release drospirenone tablet composition |
AR128632A1 (es) * | 2022-03-01 | 2024-05-29 | Chemo Res S L | Anticonceptivo oral masticable de drospirenona |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2652761C2 (de) | 1976-11-16 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
DE3051168C2 (de) * | 1979-01-24 | 1998-08-27 | Minnesota Mining & Mfg | Mono- bzw. Polycarbonsäureester oder deren Gemische oder Ester bzw. deren Gemische aus Isocyanaten und fluor- bzw. chlorhaltigen aliphatischen Alkoholen |
DE3051166C2 (en) | 1980-06-11 | 1990-10-18 | Schering Ag, 1000 Berlin Und 4709 Bergkamen, De | Compsns. for contraception or treatment of gynaecological disorders |
DE3347125A1 (de) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
DE3682130D1 (de) * | 1985-07-15 | 1991-11-28 | Japan Res Dev Corp | Verfahren zur herstellung von ultrafeinen organischen verbindungen. |
DE3916112A1 (de) | 1989-05-16 | 1990-11-22 | Schering Ag | Dihydrospirorenon als antiandrogen |
DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
DK95093D0 (da) * | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
ZA939566B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for dry blend compression od medicaments. |
DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
DE4411585A1 (de) | 1994-03-30 | 1995-10-05 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
DE69530308T2 (de) * | 1994-09-22 | 2003-10-16 | Akzo Nobel Nv | Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung |
DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
US5897539A (en) * | 1995-09-28 | 1999-04-27 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
ATE271386T1 (de) * | 1996-07-26 | 2004-08-15 | Wyeth Corp | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält |
WO1998004267A1 (en) * | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
IL127923A (en) * | 1996-07-26 | 2004-07-25 | Wyeth Corp | Pharmaceutical preparation swallowed to prevent pregnancy |
DE19633685C1 (de) | 1996-08-12 | 1997-10-09 | Schering Ag | Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens |
DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
JP4354667B2 (ja) * | 1999-08-31 | 2009-10-28 | バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト | 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ |
MXPA02006613A (es) * | 2000-01-18 | 2003-10-15 | Schering Ag | Drospirenona para terapia de reemplazo de hormonas. |
-
2000
- 2000-08-31 JP JP2001519915A patent/JP4354667B2/ja not_active Expired - Lifetime
- 2000-08-31 PT PT03017743T patent/PT1380301E/pt unknown
- 2000-08-31 ES ES00953387T patent/ES2211580T3/es not_active Expired - Lifetime
- 2000-08-31 DE DE200912000007 patent/DE122009000007I2/de active Active
- 2000-08-31 EP EP03017743A patent/EP1380301B1/en not_active Revoked
- 2000-08-31 NZ NZ51784500A patent/NZ517845A/xx not_active IP Right Cessation
- 2000-08-31 DE DE200912000006 patent/DE122009000006I2/de active Active
- 2000-08-31 PT PT00953387T patent/PT1214076E/pt unknown
- 2000-08-31 DK DK03017743T patent/DK1380301T3/da active
- 2000-08-31 EE EEP200200110A patent/EE05128B1/xx not_active IP Right Cessation
- 2000-08-31 ES ES03017743T patent/ES2319750T3/es not_active Expired - Lifetime
- 2000-08-31 DE DE60006692T patent/DE60006692T2/de not_active Expired - Lifetime
- 2000-08-31 RS RSP-2009/0134A patent/RS20090134A/sr unknown
- 2000-08-31 ES ES05076943T patent/ES2325589T3/es not_active Expired - Lifetime
- 2000-08-31 PL PL354406A patent/PL199028B1/pl unknown
- 2000-08-31 SI SI200031034T patent/SI1598069T1/sl unknown
- 2000-08-31 IL IL14833900A patent/IL148339A0/xx active IP Right Grant
- 2000-08-31 KR KR1020027002795A patent/KR100857344B1/ko active IP Right Review Request
- 2000-08-31 DE DE60041421T patent/DE60041421D1/de not_active Expired - Lifetime
- 2000-08-31 RS YU14502A patent/RS50262B/sr unknown
- 2000-08-31 PT PT05076943T patent/PT1598069E/pt unknown
- 2000-08-31 RS RS14502A patent/RS50262B2/sr unknown
- 2000-08-31 WO PCT/IB2000/001213 patent/WO2001015701A1/en active Search and Examination
- 2000-08-31 AT AT05076943T patent/ATE429231T1/de active
- 2000-08-31 ME MEP-360/08A patent/MEP36008A/xx unknown
- 2000-08-31 EP EP00953387A patent/EP1214076B1/en not_active Revoked
- 2000-08-31 DE DE60042089T patent/DE60042089D1/de not_active Expired - Lifetime
- 2000-08-31 ME MEP-2008-360A patent/ME00329B/me unknown
- 2000-08-31 KR KR1020077013070A patent/KR101019361B1/ko active IP Right Review Request
- 2000-08-31 AT AT00953387T patent/ATE254464T1/de active
- 2000-08-31 EP EP05076943A patent/EP1598069B1/en not_active Revoked
- 2000-08-31 SI SI200030308T patent/SI1214076T1/xx unknown
- 2000-08-31 CZ CZ20020615A patent/CZ300514B6/cs not_active IP Right Cessation
- 2000-08-31 AU AU65895/00A patent/AU780330B2/en not_active Expired
- 2000-08-31 EP EP08015966A patent/EP2044941A1/en not_active Withdrawn
- 2000-08-31 BR BR0014159-3A patent/BR0014159A/pt not_active Application Discontinuation
- 2000-08-31 SI SI200031021T patent/SI1380301T1/sl unknown
- 2000-08-31 AT AT03017743T patent/ATE420648T1/de active
- 2000-08-31 DK DK00953387T patent/DK1214076T3/da active
- 2000-08-31 DK DK05076943T patent/DK1598069T3/da active
- 2000-08-31 HU HU0202500A patent/HU227207B1/hu unknown
- 2000-11-16 TW TW089124254A patent/TWI276436B/zh not_active IP Right Cessation
-
2002
- 2002-02-19 NO NO20020801A patent/NO326860B1/no not_active IP Right Cessation
- 2002-12-12 HK HK02109000.7A patent/HK1047247B/zh not_active IP Right Cessation
-
2004
- 2004-07-08 HK HK04104970.2A patent/HK1061968A1/xx not_active IP Right Cessation
-
2005
- 2005-05-13 AU AU2005202046A patent/AU2005202046B9/en not_active Expired
-
2006
- 2006-04-24 HK HK06104833.7A patent/HK1082432A1/xx not_active IP Right Cessation
- 2006-11-23 BG BG109749A patent/BG66114B1/bg unknown
-
2007
- 2007-05-04 HR HRP20070188AA patent/HRP20070188B1/hr not_active IP Right Cessation
-
2009
- 2009-01-22 AU AU2009200247A patent/AU2009200247B2/en not_active Expired
- 2009-03-02 JP JP2009048381A patent/JP2009143959A/ja active Pending
- 2009-04-14 CY CY20091100446T patent/CY1108990T1/el unknown
- 2009-07-22 CY CY20091100784T patent/CY1109252T1/el unknown
- 2009-09-25 CY CY2009015C patent/CY2009015I2/el unknown
-
2010
- 2010-10-01 AU AU2010226924A patent/AU2010226924A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108990T1 (el) | Φαρμακευτικος συνδυασμος αιθινυλεστραδιολης και δροπιρενονης για χρηση ως αντισυλληπτικο | |
CY1120313T1 (el) | Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες | |
BR0015188A (pt) | Composições farmacêuticas | |
DK1183014T3 (da) | Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse | |
BG66095B1 (bg) | Хидрофилен състав с контролирано освобождаване съдържащ прежелатинирано нишесте в препарат | |
NO327588B1 (no) | Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel | |
MX9706449A (es) | Composicion farmaceutica para compuestos de piperidinalcanol. | |
ATE287264T1 (de) | Oral anzuwendende buprenorphinhaltige arzneimittel | |
ATE252377T1 (de) | Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff | |
PT837684E (pt) | Composicoes farmaceuticas a base de um sal de diclofenac e de tiocolchicosido | |
AR049196A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
EA200701389A1 (ru) | Твёрдая пероральная лекарственная форма для контрацепции | |
MX2007009061A (es) | Preparacion farmaceutica para la anticoncepcion oral. | |
JO2213B1 (en) | A pharmaceutical composition for use as a contraceptive method | |
CA2248841A1 (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
BR0311209A (pt) | Método de produção de unidades de dosagem farmacêuticas para administração oral, uso de etonogestrel, e, tablete | |
AR025443A1 (es) | Una composicion farmaceutica para ser usada como anticonceptivo. | |
EP2305267A3 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
UY29378A1 (es) | Preparación farmaceutica para la anticoncepción oral | |
HRP20020666B1 (en) | Drospirenone for hormone replacement therapy | |
TH80557B (th) | ผลิตภัณฑ์ทางเภสัชกรรมสำหรับการคุมกำเนิดทางช่องปาก | |
TH54054B (th) | สารผสมทางเภสัชกรรมสำหรับใช้เป็นยาคุมกำเนิด |